

CONTROL OF ENVIRONMENTAL HEALTH AND REMOVAL OF RATS BY α_2 -ADRENERGIC ANTAGONIST AND POTASSIUM CHANNEL BLOCKER

*¹M. Khosravi, ¹S. Oryan, ²S.A. Haeri Rohani, ¹K. Parivar, ³R. Marandi

¹Science and Research Branch, Islamic Azad University, Tehran. Iran

²Department of Biology, Tehran University, Tehran. Iran

³North Tehran Branch, Islamic Azad University, Tehran, Iran

Received 18 May 2006; revised 10 June 2006; accepted 26 August 2006

ABSTRACT

In the present study, it is shown that in vivo oral administration of glibenclamide (1-10 mg/kg/day), an adenosine triphosphate-sensitive potassium channel blocker, and yohimbine (1-5 mg/kg/day), an alpha 2-adrenoceptor antagonist, potently reduced glycemia in male rats. Diazoxide (1-45 mg/kg/day), a potassium channel opener, and clonidine (0.05-0.5 mg/kg/day), an alpha 2-adrenoceptor agonist, antagonized the effects of glibenclamide and yohimbine respectively. Administration of glibenclamide and yohimbine separately decreased the serum glucose levels, so it was expected that coadministration of these two drugs significantly decreased this parameter in fasted animals. It is well known that glibenclamide blocks the potassium channels and it is likely that, yohimbine also blocks these channels, but according to our data, it seems that yohimbine acts via a different binding site to that of glibenclamide. In this research it is also observed that administration of yohimbine and glibenclamide causes death in rats, it seems that these drugs causes death in the experimental animals by lowering blood glucose level, which were the aim of this study and could be applied as a way to control the environmental health by abolishing rats.

Key words: Rats, K_{ATP} channel, glibenclamide, yohimbine, environmental health

INTRODUCTION

In stress, sympathetic system stimulation inhibits insulin release via postsynaptic alpha 2 (α_2)-adrenoceptors on the pancreas beta cells, intense sympathetic stimulations interrupt the activation of beta cells in type 2 diabetes mellitus (DM). Some of the researchers believe that pretreatment with clonidine potentiated hyperglycemia. Glycogenolysis and gluconeogenesis or decrease of glucose intake by tissue cells (increase of growth hormone and epinephrine) may induce the increase of blood glucose (Hiyoshi *et al.*, 1995). In this research, administration of yohimbine (Yo) (α_2 -adrenoceptor antagonist) separately or combined with glibenclamide (Gl) (adenosine triphosphate (ATP)-sensitive potassium channel (K_{ATP} channel) blocker) could decrease blood glucose. By this idea, that administration of Yo and Gl may causes death

of rats; oral administration of this drug may be a biologic way to defend against these animals. Archeologic studies have shown that rats were contemporain with human being in the third period of geology. In addition that rats are one of the pests of agricultural products, and produce severe damages to channels, buildings, cable wires and etc. Also data have shown that 35 diseases such as thyfus, peste, bite fever, jaundice, thyphoid, diarrhea, cholera, webbel, pig worm, trishin are transported by rats. The susceptibility of persons is depended to individual resistance, kind and number of microbes. The risk of getting diseases is potentiated by using infected food, because foods are easily infected by waste materials, body hair and urine of the animals. To prevent the propagation of diseases transported by rats, hygienic items must be considered. Foods with animal origin must be cooked very well done. Meal

*Corresponding author-Email: maryam.khosravi@yahoo.com

Tel: +98 21 2294 2275

products must be observed very carefully in the butcheries and food stores should be out of the reach of rodents (Ahmadbeygui, 1379).

Studies and experiments have shown that a pair of rat (male and female) in one year can produce a family with five hundred members. Cleaning the eges, environment promoting, physical and chemical fights, electrical and ultra-violet trapping and use of ultrasound are one of the ways to defend against rodents. These models of fights are used to reduce the rat's number and preventing the propagation of diseases common between human and animals easily. Foods containing anticoagulant or toxins can be used for domestic and semi-domestic rodents. But always we should be careful about the health of human and animals in reach with toxins (Ahmadbeygui, 1379). Chemical toxins are technological products which pollute the environment. In some countries, use of toxins for rats is irradiated and to maintain life environment hygiene, use of these toxins is forbidden. But in Iran these methods are already current and is better that, non-chemical specially biologic methods be used because they can produce a minimal damage for the environment. Natural toxins also can effect with lower doses, can be analysed faster in the nature and can damage a little the environment. At the end, the methods for fighting the rats should be cheap. Chemical toxins are divided into two groups: acute and chronic toxins (Ahmadbeygui, 1379; Ashaghi, 1384). Acute chemical toxins such as Arsenic oxide and strychnine (with high toxicity), Talium sulfate, Aneto, phosphore de zinc (with moderate toxicity), Rodascoil (with low toxicity) chronic chemical toxins such as anticoagulants for example varfarine, comatetricile, chlorate, lanivate and actocine. The mechanism of these toxins is inhibiting prothrombine formation (an anticoagulant factor) (Ahmadbeygui, 1379; Ashaghi, 1384).

One of the α_2 -adrenoceptor selective blocker is yohimbine. Yohimbine is an indole and the principal alkaloid from the bark of the west-african tree *Pausinystalia Yohimbe* Pierre (Formerly *Corynanthe yohimbe*) family Rubiaceae (madder family). Yohimbine has many effects on the central nervous system and body organs. This drug has parasympathomimetic effect and can induce

parasympathetic activation. The yohimbine effects are anxiety, hypertension, tachycardia, locomotion, erection and convulsion.

Glibenclamide is one of the sulfonylureas of second-generation and the blocker of K_{ATP} channels. The K_{ATP} channel on the beta cell consists of a hetero-octomeric complex of four pore subunits, which are known as inwardly rectifying potassium 6.2 ($K_{ir6.2}$), and four regulatory, or sulfonylurea receptor 1 (SUR1), subunits. These drugs bind to the SUR1 subunit of KATP channel and by blocking these channels, depolarize the cell membrane, opens calcium voltage dependent channels and increase intracellular calcium, then vesicles containing insulin are transported to the cell membrane and secreted out of the cell (Doyle and Egan, 2003; Eliasson, et al., 1997). In the presence of sulfonylureas the activation of K_{ATP} channel even in the absence of glucose is stopped and it evokes hypoglycemia in all conditions. When the half-life of sulfonylureas special analogue is longer the possibility of inducing hypoglycemia is more enhanced (Eliasson, et al., 1996). There is evidence that some sulfonylureas actually enhance the usual inhibitory action that MgADP (magnesium-adenosine diphosphate) has on the nucleotide binding site of the $K_{ir6.2}$ subunit and so this may increase insulin release even more under hypoglycemic conditions. MgADP effects on the K_{ATP} channel are 2-fold: it inhibits the $K_{ir6.2}$ subunit and stimulates the SUR1 activity. However, in the presence of some sulfonylureas, the interaction of MgADP with SUR1 is diminished, resulting in its unopposed inhibitory effect on $K_{ir6.2}$ (Doyle and Egan, 2003).

MATERIALS AND METHODS

In the present study, normal male wistar rats (170-230 g) purchased from Pasteur institute of Iran, were kept under a 12-h light/dark cycle. Water and food were available, and the room temperature was 21-25 degree of centigrade. Animals were divided into groups of six rats. Drugs used in this study were:

- Clonidine hydrochloride from Tolid Darou company.
- Yohimbine hydrochloride from Iran Darou company.

- Glibenclamide hydrochloride from Tehran Chimie company.
- Diazoxide from Razak company.

Clonidine and yohimbine are soluble in water. Each day, glibenclamide and diazoxide were prepared in the solvent. The solvent for 30 mg diazoxide was: NaOH 0.9^{cc} (0.1 N). The solvent for 30 mg glibenclamide was: 0.6mL (1M) NaOH + 1mL ethanol + 1mL polyethylenglycol 400 + 0.4mL H₂O.

Instruments and kits

- Digital spectrophotometer (uv ikon) model 922 with computing monitor.
- Glucose diagnostic kit from biochemistry company and insulin diagnostic kit from Kavoshyar company.

Treatment

Drug administration: One night before drug administration, the animals were deprived from food. Then all the groups received oral administration of the drug for one week. In this period of time, water and food were available for the animals including control group. **Blood sampling:** Rats were anesthetized with ether then blood was sampled from the retro orbital sinus. The blood sample were clotted in the laboratory. Then, the samples were centrifuged for 15 minutes with a speed of 3000/min. Serum glucose level was measured by glucose oxidase (Enzymatic, colorimetric-GOD-PAP, Cat no. 10505 Biochemical). Glucose level was measured with spectrophotometer based on enzymatic method and color intensity with glucose oxidation.

Statistical analysis

All data were reported as means \pm SEM. Differences between groups were examined by one-way analysis of variance (ANOVA) with Tukey test at a significance of * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

RESULTS

Different doses of glibenclamide (K channels blocker) 1, 3, 5, 10 mg/kg administrated to male rats, decrease glucose serum dose dependently and the more effective dose was 5 mg/kg. Different doses of diazoxide (K channels opener) 1, 15, 30, 45 mg/kg increase glucose serum dose dependently and the more effective dose was 30

mg/kg. Clonidine (alpha-2 adrenoreceptor agonist) 0.05, 0.1, 0.25, 0.5 mg/kg increase glucose serum dose dependently and the more effective dose was 0.25 mg/kg, and different doses of yohimbine (alpha-2 adrenoreceptor antagonist) 1, 2, 5 mg/kg decrease glucose serum dose dependently and the more effective dose was 2 mg/kg. In these experiments, it is shown that there is no significant difference of glucose level between control and sham group (intact). But there is significant difference of glucose levels in the groups administrated by glibenclamide (Gl), diazoxide (Di), clonidine (Cl), yohimbine (Yo) comparing with their sham groups in Figs. 1 to 5. There is no significant difference of glucose level in the groups receiving glibenclamide + diazoxide or clonidine + yohimbine comparing with their sham groups. And also, it is shown that there is no significant difference of glucose level between control and group receiving Gl + Cl or Yo + Di. But there is a significant increase of glucose level comparing control and groups receiving Di and Cl in Figs. 6 to 8.




Fig. 1: Effects of different doses of glibenclamide in the blood glucose serum of the fasted male rats.




Fig. 2: Effects of different doses of diazoxide in the blood glucose serum of the fasted male rats.




Fig. 3: Effects of different doses of clonidine in the blood glucose serum of the fasted male rats.




Fig. 4: Effects of different doses of yohimbine in the blood glucose serum of the fasted male rats.




Fig. 5: Effects of optimum doses of different drugs in the blood glucose serum of the fasted male rats.




Fig. 7: Effects of glibenclamide + clonidine , glibenclamide + yohimbine , diazoxide + clonidine and diazoxide + yohimbine in the blood glucose serum of the fasted male rats.




Fig. 6: Effects of glibenclamide + diazoxide and clonidine + yohimbine in the blood glucose serum of the fasted male rats




Fig. 8: Effects of glibenclamide , yohimbine and effects of glibenclamide + yohimbine in the blood glucose serum of the fasted male rats.

DISCUSSION

In this study, glibenclamide (K channels blocker) decreases glucose level dose-dependently. 5 mg/kg of this drug was used as the optimum dose, because in these experiments the lowest glucose serum level was obtained after using this dose of drug. These results are consistent with the results of previous studies (Tian, *et al.*, 1998; Eliasson, *et al.*, 1997). In 1996 it was reported that the action of sulfonylureas may not be entirely limited to closure of the K_{ATP} channels, but that they may have a direct effect on the exocytotic machinery of the beta cells. The effect is protein kinase C (PKC)-dependent (Eliasson, *et al.*, 1996) but may not involve activation of PKC (Tian, *et al.*, 1998). Renstrom and colleagues have proposed that it is associated with the maintenance in the insulin vesicles of a pH and ion balance conducive to exocytosis (Renstrom, *et al.*, 2002). Acidification of the internal milieu of the insulin vesicle occurs via uptake of H^+ and is a necessary priming step for release of insulin. This increase in positive charge within the vesicle must be balanced by an influx of Cl^- to prevent an excessive build-up of positive charge and thus permit vesicle acidification. Sulfonylureas are known to bind to a 65-KDa protein found on the vesicle fraction of the beta cell. (Kramer, *et al.*, 1994) which is instrumental in the acidification of the insulin vesicle. Diazoxide also increase blood glucose dose dependently, and the more effective dose of this drug was 30 mg/kg. These results are in agreement with the previous studies (Clapham, *et al.*, 1994). Diazoxide is the more potent opener of K_{ATP} channels and its effect are contrast to sulfonylureas. Diazoxide hyperpolarizes beta cells and after inhibiting insulin secretion, cause hyperglycemia. This drug opens K_{ATP} channels by the presence of Mg^{2+} and ATP and it seems that these channels have a different binding site than suffonylureas (Doyle and Egan, 2003). The coadministration of optimum doses of glibenclamide and diazoxide (5,30 mg/kg) show that the hypoglycemia induced by glibenclamide is antagonized with diazoxide. These results agree with the studies of Tian *et al.*, 1998 and demonstrate that glibenclamide can block K_{ATP} channel and diazoxide is capable to open it.

According to the results of the present research, clonidine (alpha-2 adrenoreceptor agonist) increased blood glucose serum dose dependently, and the more effective dose of this drug was 0.25 mg/kg. These results are in agreement with the previous studies of O'Dannell, *et al.*, 1996. It seems that α_2 -receptors, inhibit adenylyl cyclase activation via the inhibiting regulatory G_i protein (inhibitory G protein). The mechanism which G_i inhibits adenylyl cyclase is not exactly known. But there are two probabilities:

- The free subunits beta-gamma of G_i protein bind to alpha subunit of G_s protein (stimulatory G protein) and inhibit it.
- Alpha subunits of G_i protein inhibit directly adenylyl cyclase activation.

Some researchers accept both of these two mechanisms. In addition, some of the effects of alpha-2 adrenoceptors are not due via adenylyl cyclase inhibiting, these mechanisms include opening of the potassium and closing of the calcium channels. Perhaps these effects are due to the function of the beta-gamma subunits of G_i protein, which are due via ion channels and enzymes. Stimulation of the alpha-2 adrenoceptors in the beta cells is believed to directly activate a G-protein-gated K channel, there by inhibiting exocytosis (Doyle and Egan, 2003). On the other hand, clonidine potentiates the inhibiting effect of adenylyl cyclase on insulin secretion and also it seems that clonidine by glycogenolysis and gluconeogenesis in liver cells causes hyperglycemia. These results show that yohimbine (alpha-2 adrenoceptor antagonist) decreased blood glucose serum dose dependently, and the optimum dose of this drug was obtained 2 mg/kg. These results are in agree with the studies of other researchers (Jonas, *et al.*, 1994, Efanove, *et al.*, 2001). It seems that alpha-2 adrenoceptor antagonists increase insulin release from beta cells of pancreas islets, and probably some of the imidazolines release insulin via closing the K_{ATP} channels and voltage dependent K channels. Some of the investigators believe that the binding site of imidazoline is not the same as alpha-2 adrenoceptor in beta cells (Chan, 1998). Some of the researchers believe that imidazoline receptor is one of the part of K_{ATP}

channel on beta cells (Olmos, *et al.*, 1994). Two mechanisms may have a role in insulin release induced by yohimbine. 1- In low concentration increases insulin which may induce by alpha-2 adrenoceptor blocking. 2- In high concentration increases insulin which may induce by K_{ATP} channels blocking (Jonas *et al.*, 1994). The results from effects of coadministration of optimum doses of clonidine and yohimbine (0.25 and 2 mg/kg) show that clonidine limits and blocks blood glucose serum decreasing. So, after inhibiting the effect of yohimbine by clonidine, blood glucose serum approach to the glucose level of sham groups. These results agree with the findings of O'Dannell, *et al.*, 1996. In the present study coadministration of yohimbine and clonidine, prevent hyperglycemia induced by clonidine, so it seems that in addition of previous mechanisms, yohimbine via blocking the postsynaptic alpha-2 adrenoceptor of beta cells has prevented the inhibition of adenylyl cyclase and increased the intracellular cyclic adenosine monophosphate (cAMP). Also the results of coadministration of yohimbine and diazoxide show that yohimbine prevents the hyperglycemia induced by diazoxide. It seems that probably yohimbine like imidazolines binds to a different site of $K_{ir6.2}$ subunit (subunit forming the channel pore) and blocks the channel. The experimental results in this study show that the coadministration of yohimbine and glibenclamide cause death in rats probably due to the decrease of blood glucose plasma concentration. These drugs are not as harmful and pollutant as the other animal toxins for human being. On the other hand, these drugs are biologic, easily analysed in the environment, cheap, available and could be easily added to the food or water of the animals. So it is suggested that in the future researches, the effects of these drugs could be studied as a chemical method to control the pollution of big cities such as Tehran. Adding the supplements to the above mentioned drugs are the future targets of this study and could be extended throughout the country.

REFERENCES

- Ahmadbeygui, N., (1379). Mice family (MURINAE) in TRAN., North Tehran campus, Azad university, Mechanic faculty.
- Ashaghi, M., (1384). Effects of organic-phospho pesticides on the environment, North Tehran campus, Azad university, Mechanic faculty.
- Chan, S. L., (1998). Clonidine-displacing substance and its putative role in control of insulin secretion: Minireview., *Gen. Pharmacol.*, **31**(4): 525-529.
- Clapham, J. C., Trail, B. K., Hamilton T. C., (1994). K^+ channel activators acute glucose tolerance and glibenclamide induced hypoglycemia in the hypertensive rat. *Eur. J. Pharmacol.*, **257**: 79-85.
- Doyle, M. E., Egan, J. M., (2003). Pharmacological agents that directly mediate insulin secretion. *Pharmacol. Rev.*, **55**: 105-131.
- Efanov, A. M., Hoy, M., Branstrom, R., Zaitsev, S. V., Magnuson, M. A., Efendic, S., Gromada, J., Berggren, P.O., (2001). The imidazoline RX871024 stimulates insulin secretion in pancreatic B-cells from mice deficient in K_{ATP} channel function. *Biochem. Biophys. Res. Comm.*, **284**: 918-922.
- Eliasson, L., Renstrom, E., Ammala, C., Berggren, P. O., Bertorello, A. M., Bokvist, K., Chibalin, A., Deeney, J. T., Flatt, P. R., Gabel, J., (1996). PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic beta cells., *Science (Wash DC)*, **271**: 813-815.
- Eliasson, L., Renstrom, E., Ding, W. G., Proks, P., Rorsman, P., (1997). Rapid ATP dependent priming of secretory granules precedes Ca^{2+} induced exocytosis in mouse pancreatic β -cells. *J. Physiol. (Lond)*, **503**: 399-412.
- Hiyoshi, Y., Miura, H., Uemura, K., Endo, H., Ozawa, K., Maeda, N., Tamagawa, T., Iguchi, A., (1995). Effects of imidazoline antagonists of α_2 -adrenoceptors on endogenous adrenaline-induced inhibition of insulin release. *Eur. J. pharmacol.*, **294**: 117-123.
- Jonas, J. C., Plant, T. D., Angel, I., Langer, S. Z., Henquin, J. C., (1994). In Vitro stimulation of insulin release by SL 84.0418, a new α_2 -adrenoceptor antagonist. *Eur. J. pharmacol.*, **254**: 27-33.
- Kramer, W., Muller, G., Girbig, F., Gutjahr, U., Kowalewski, S., Hartz, D., Summ, H. D., (1994). Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor II. Photoaffinity labeling of a 65 kDa protein by (3H) glimepiride. *Biochim. Biophys. Acta.*, **1191**: 278-290.
- O'Dannell, J. M., Banyasz, T., Kovacs, T., (1996). Altered thermoregulatory responses to clonidine in streptozotocin-diabetic rats. *Br. J. Pharmacol.*, **117**: 938-942.
- Olmos, G., Kulkarni, R. N., Haque, M., MacDermot, J., (1994). Imidazolines stimulate release of insulin from RIN-5AH cells independently from imidazoline I1 and I2 receptors. *Eur. J. Pharmacol.*, **262** (1-2): 41-8.
- Renstrom, E., Barg, S., Thevenod, F., Rorsman, P., (2002). Sulfonylurea-mediated stimulation of insulin exocytosis via an ATP-sensitive $K(+)$ channel-independent action. *Diabetes.*, **51**: S33-S36.
- Tian, Y. A., Johnson, G., Ashcroft, S. J., (1998). Sulfonylureas enhance exocytosis from pancreatic beta-cells by a mechanism that does not involve direct activation of protein kinase C. *Diabetes.*, **47**: 1722-1726.